The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial
Open accessAbstract
Background: Two recent clinical studies support the feasibility of trials to evaluate the disease-modifying properties of lithium in Alzheimer's disease, although no benefits were obtained from short-term treatment. Aims: To evaluate the effect of long-term lithium treatment on cognitive and biological outcomes in people with amnestic mild cognitive impairment (aMCI). Method: Forty-five participants with aMCI were randomised to receive lithium (0.25–0.5 mmol/l) ( n = 24) or placebo ( n = 21) in a 12-month, double-blind trial. Primary outcome measures were the modification of cognitive and functional test scores, and concentrations of cerebrospinal fluid (CSF) biomarkers (amyloid-beta peptide (Aβ 42 ), total tau (T-tau), phosphorylated-tau) (P-tau). Trial registration: NCT01055392. Results: Lithium treatment was associated with a significant decrease in CSF concentrations of P-tau ( P = 0.03) and better perform-ance on the cognitive subscale of the Alzheimer's Disease Assessment Scale and in attention tasks. Overall tolerability of lithium was good and the adherence rate was 91%. Conclusions: The present data support the notion that lithium has disease-modifying properties with potential clinical implications in the prevention of Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Roth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
Morris, J. C., Mohs, R. C., Rogers, H., Fillenbaum, G. G., & Heyman, A. (1988) · PubMed · Cited by 1,131
Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3
Hong, M., Chen, D. C. R., Klein, P. S., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25326 · Cited by 469
Glycogen synthase kinase 3: a drug target for CNS therapies
Bhat, R. V., Budd Haeberlein, S. L., & Avila, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02422.x · Cited by 408
Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T., & Imahori, K. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81066-9 · Cited by 402
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder
Nunes, P. V., Forlenza, O. V., & Gattaz, W. F. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.029868 · Cited by 368
Self-citationHampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
Hampel, H., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04606 · Cited by 295
Rockenstein, E., Torrance, M., Adame, A., Mante, M., Bar-on, P., Rose, J. B., Crews, L., & Masliah, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4321-06.2007 · Cited by 288
Lithium Treatment and Risk of Dementia
Kessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.11.1331 · Cited by 267
Scoring Reliability on the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III)
Ryan, J. J., & Schnakenberg-Ott, S. D. (2003) · Assessment · doi:10.1177/1073191103010002006 · Cited by 221
Does lithium protect against dementia?
Kessing, L. V., Forman, J. L., & Andersen, P. K. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00788.x · Cited by 204
Diniz, B. S. O., Pinto, J. A., & Forlenza, O. V. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701535502 · Cited by 170
Self-citationLovestone, S., Davis, D. R., Webster, M.-T., Kaech, S., Brion, J., Matus, A. I., & Anderton, B. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00183-8 · Cited by 166
Endpoints for trials in Alzheimer's disease: a European task force consensus
Vellas, B. J., Andrieu, S., Sampaio, C., Coley, N., & Wilcock, G. K. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70087-5 · Cited by 165
A feasibility and tolerability study of lithium in Alzheimer's disease
Macdonald, A., Briggs, K., Poppe, M., Higgins, A. R., Velayudhan, L., & Lovestone, S. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1964 · Cited by 163
Disease-modifying trials in Alzheimer's disease: a European task force consensus
Vellas, B. J., Andrieu, S., Sampaio, C., & Wilcock, G. K. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70677-9 · Cited by 157
Glycogen synthase kinase‐3β, or a link between amyloid and tau pathology?
Muyllaert, D., Kremer, A., Jaworski, T., Borghgraef, P., Devijver, H., Croes, S., Dewachter, I., & Leuven, F. V. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00376.x · Cited by 152
Does Lithium Protect Against Dementia
Dubovsky, S. L. (2008) · Journal watch · doi:10.1056/jp200812220000002 · Cited by 137
Halstead-Reitan Neuropsychological Test Battery
Hussey, J., & Allen, D. N. (2018) · Springer eBooks · doi:10.1007/978-3-319-57111-9_189 · Cited by 131
Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3
Koh, S., Noh, M., & Kim, S. H. (2007) · Brain Research · doi:10.1016/j.brainres.2007.10.064 · Cited by 129
Mild cognitive impairment: cognitive screening or neuropsychological assessment?
Diniz, B. S., Nunes, P. V., Yassuda, M. S., Pereira, F., Flaks, M. K., Viola, L. F., Radanovic, M., de Abreu, I. D., Borelli, D. T., Gattaz, W. F., et al. (2008) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462008000400003 · Cited by 91
Self-citationChuang, D., & Manji, H. K. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.008 · Cited by 60
Cited by
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
The Inositol Trisphosphate/Calcium Signaling Pathway in Health and Disease
Berridge, M. J. (2016) · Physiological Reviews · doi:10.1152/physrev.00006.2016 · Cited by 753
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Metadata
- Authors
- Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2011-05
- Volume
- 198
- Issue
- 5
- Pages
- 351-356
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2037053607
- Cited by
- 402
- References
- 30
- FWCI
- 21.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.